Efavirenz enhances the proteolytic processing of an HIV‐1 pol polyprotein precursor and reverse transcriptase homodimer formation
- 14 December 2004
- journal article
- Published by Wiley in FEBS Letters
- Vol. 579 (2) , 379-384
- https://doi.org/10.1016/j.febslet.2004.11.099
Abstract
The non-nucleoside reverse transcriptase inhibitor, efavirenz (EFV), is a potent enhancer of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) p66/p51 heterodimerization. While the mechanism of RT heterodimer formation in HIV-1 infected cells is not completely understood, it has been speculated that Gag-Pol/Gag-Pol and/or RT homodimer interactions may represent important intermediates in the pathway. To elucidate whether EFV impacts on these interactions, we have evaluated the effects of this drug on RT homodimer interactions and HIV-1 Gag-Pol processing. EFV, but not nevirapine, significantly enhanced RT p66/p66 and p51/p51 homodimer interactions and accelerated the proteolytic cleavage of a model HIV-1 Pol polyprotein precursor expressed in bacteria. These data suggest that potent mediators of RT dimerization might interfere with the late-stages of viral replication.Keywords
This publication has 37 references indexed in Scilit:
- Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formationThe International Journal of Biochemistry & Cell Biology, 2004
- The Dimer Interfaces of Protease and Extra-Protease Domains Influence the Activation of Protease and the Specificity of GagPol CleavageJournal of Virology, 2003
- The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.1Antiviral Research, 1998
- Hydrophilic Peptides Derived from the Transframe Region of Gag-Pol Inhibit the HIV-1 ProteaseBiochemistry, 1998
- A Transient Precursor of the HIV-1 ProteaseJournal of Biological Chemistry, 1996
- Conformational stability of dimeric HIV-1 and HIV-2 reverse transcriptasesBiochemistry, 1995
- Locations of Anti-AIDS Drug Binding Sites and Resistance Mutations in the Three-dimensional Structure of HIV-1 Reverse TranscriptaseJournal of Molecular Biology, 1994
- Crystal Structure at 3.5 Å Resolution of HIV-1 Reverse Transcriptase Complexed with an InhibitorScience, 1992
- Autoprocessing of the HIV‐1 protease using purified wild‐type and mutated fusion proteins expressed at high levels in Escherichia coliEuropean Journal of Biochemistry, 1991
- Characterization of Highly Immunogenic p66/p51 as the Reverse Transcriptase of HTLV-III/LAVScience, 1986